GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Construction In Progress

CARISMA Therapeutics (FRA:W2J) Construction In Progress : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Construction In Progress?

CARISMA Therapeutics's annual construction in progress stayed the same from Dec. 2022 (€0.01 Mil) to Dec. 2023 (€0.01 Mil) but then declined from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.00 Mil).


CARISMA Therapeutics Construction In Progress Historical Data

The historical data trend for CARISMA Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Construction In Progress Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Construction In Progress
- 0.01 0.01 0.01 -

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

CARISMA Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


CARISMA Therapeutics Business Description

Traded in Other Exchanges
Address
3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines